Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Scientific Reports
|
March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
Clinical Genitourinary Cancer
|
May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Minerva Urology and Nephrology
|
August 5, 2020
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
Mauro Gacci, Michele Marchioni, Piergustavo DE Francesco, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Frontiers in Cardiovascular Medicine
|
November 13, 2023
Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
Irma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Frontiers in Cardiovascular Medicine
|
October 3, 2023
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
Irma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
NPJ Breast Cancer
|
May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study
Eriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Scientific Reports
|
March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
Clinical Genitourinary Cancer
|
May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Minerva Urology and Nephrology
|
August 5, 2020
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
Mauro Gacci, Michele Marchioni, Piergustavo DE Francesco, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Frontiers in Cardiovascular Medicine
|
November 13, 2023
Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
Irma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Frontiers in Cardiovascular Medicine
|
October 3, 2023
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
Irma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
NPJ Breast Cancer
|
May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study
Eriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Page
of 8